Five Prime Therapeutics Company Profile (NASDAQ:FPRX)

About Five Prime Therapeutics (NASDAQ:FPRX)

Five Prime Therapeutics logoFive Prime Therapeutics, Inc. is a clinical-stage biotechnology company focused on discovering and developing protein therapeutics. The Company's product candidates include Cabiralizumab (FPA008), which is an antibody that inhibits colony stimulating factor-1 receptor, that it is studying in clinical trials as a monotherapy in pigmented villonodular synovitis, and in multiple cancers in combination with programmed-death 1 immune checkpoint inhibitor, Opdivo; FPA144, which is an antibody that inhibits fibroblast growth factor receptor 2b, that it is initially developing to treat patients with gastric (stomach) cancer and is in a Phase I clinical trial, and FP-1039, which is a fusion protein that traps and neutralizes cancer-promoting fibroblast growth factors, involved in cancer cell proliferation and new blood vessel formation and is in Phase Ib clinical development to treat patients with malignant pleural mesothelioma. Its preclinical programs include FPA150, FPA154 and FPT155.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Bio Therapeutic Drugs
  • Sub-Industry: N/A
  • Symbol: NASDAQ:FPRX
  • CUSIP: N/A
  • Web: www.fiveprime.com
Capitalization:
  • Market Cap: $1.35088 billion
  • Outstanding Shares: 27,985,000
Average Prices:
  • 50 Day Moving Avg: $36.50
  • 200 Day Moving Avg: $31.99
  • 52 Week Range: $25.97 - $60.98
P/E:
  • Trailing P/E Ratio: N/A
  • Foreward P/E Ratio: -9.59
  • P/E Growth: 0.14
Sales & Book Value:
  • Annual Revenue: $32.9 million
  • Price / Sales: 39.66
  • Book Value: $11.55 per share
  • Price / Book: 4.04
Profitability:
  • EBITDA: ($133,090,000.00)
  • Net Margins: -356.39%
  • Return on Equity: -31.78%
  • Return on Assets: -27.55%
Debt:
  • Current Ratio: 10.22%
  • Quick Ratio: 10.22%
Misc:
  • Average Volume: 306,761 shs.
  • Beta: 4.19
  • Short Ratio: 9.68
 

Frequently Asked Questions for Five Prime Therapeutics (NASDAQ:FPRX)

What is Five Prime Therapeutics' stock symbol?

Five Prime Therapeutics trades on the NASDAQ under the ticker symbol "FPRX."

How were Five Prime Therapeutics' earnings last quarter?

Five Prime Therapeutics, Inc. (NASDAQ:FPRX) issued its earnings results on Tuesday, August, 8th. The company reported ($1.58) EPS for the quarter, missing the consensus estimate of ($1.15) by $0.43. The firm earned $7.80 million during the quarter, compared to analysts' expectations of $8.32 million. Five Prime Therapeutics had a negative return on equity of 31.78% and a negative net margin of 356.39%. The firm's quarterly revenue was down 16.1% compared to the same quarter last year. During the same period in the previous year, the firm earned ($0.49) earnings per share. View Five Prime Therapeutics' Earnings History.

Where is Five Prime Therapeutics' stock going? Where will Five Prime Therapeutics' stock price be in 2017?

8 brokerages have issued 12 month target prices for Five Prime Therapeutics' shares. Their predictions range from $39.00 to $94.00. On average, they anticipate Five Prime Therapeutics' share price to reach $57.50 in the next twelve months. View Analyst Ratings for Five Prime Therapeutics.

What are analysts saying about Five Prime Therapeutics stock?

Here are some recent quotes from research analysts about Five Prime Therapeutics stock:

  • 1. According to Zacks Investment Research, "Five Prime Therapeutics, Inc. is a biotechnology company. The company focuses on the discovery and development of protein therapeutics that blocks cancer and inflammatory disease processes. It operates primarily in the United States and Canada. Five Prime Therapeutics, Inc. is based in San Francisco, California. " (10/16/2017)
  • 2. Jefferies Group LLC analysts commented, "Near-term focus is on initial Ph2 data for cabiralizumab in PVNS at ASCO. Roche’s emactuzumab in PVNS showed an ~80% RR at high dose, but resulting in 2 cases of lupus per FPRX." (5/5/2017)
  • 3. Cowen and Company analysts commented, "We believe Five Prime has amongst the leading IO drug discovery platforms in the industry. The BMS partnership provides validation. Multiple clinical readouts in 2017 provide catalysts to drive value generation. Lead asset Cabira has significant potential in solid tumors, we expect FPA144 to succeed in FGFR2b+ gastric cancer (2019), and we see high POS for Cabira in PVNS. Initiating at Outperform." (3/24/2017)
  • 4. Instinet analysts commented, "We are initiating on Five Prime Therapeutics (FPRX) with a Buy rating and a $94, 12-month target price. We recommend owning FPRX shares ahead of potentially transformational mid-2017 readouts. We anticipate 2017 data from cabiralizumab and key competitors will further de-risk cabiralizumab's anti-CSF1R mechanism in immuno-oncology, define pivotal clinical paths, establish initial market opportunities, and differentiate its safety versus competitors." (3/1/2017)

Who are some of Five Prime Therapeutics' key competitors?

Who are Five Prime Therapeutics' key executives?

Five Prime Therapeutics' management team includes the folowing people:

  • Lewis T. Williams M.D. Ph.D., Chairman of the Board, President, Chief Executive Officer
  • Marc L. Belsky, Chief Financial Officer, Senior Vice President
  • Aron Marc Knickerbocker MBA, Chief Operating Officer, Director
  • Kevin Baker Ph.D., Senior Vice President, Development Sciences
  • Helen Louise Collins M.D., Senior Vice President and Chief Medical Officer
  • Francis Willard Sarena J.D., Chief Strategy Officer and Secretary
  • Mark D. McDade, Lead Independent Director
  • Garry Nicholson, Director
  • Franklin M. Berger, Independent Director
  • Fred E. Cohen Ph.D. M.D., Independent Director

How do I buy Five Prime Therapeutics stock?

Shares of Five Prime Therapeutics can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Five Prime Therapeutics' stock price today?

One share of Five Prime Therapeutics stock can currently be purchased for approximately $46.63.


MarketBeat Community Rating for Five Prime Therapeutics (NASDAQ FPRX)
Community Ranking:  3.3 out of 5 (star star star)
Outperform Votes:  171 (Vote Outperform)
Underperform Votes:  85 (Vote Underperform)
Total Votes:  256
MarketBeat's community ratings are surveys of what our community members think about Five Prime Therapeutics and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Consensus Ratings for Five Prime Therapeutics (NASDAQ:FPRX) (How are Consensus Ratings Calculated?)
Ratings Breakdown: 8 Buy Ratings
Consensus Rating:Buy (Score: 3.00)
Consensus Price Target: $57.50 (23.31% upside)
Consensus Price Target History for Five Prime Therapeutics (NASDAQ:FPRX)
Price Target History for Five Prime Therapeutics (NASDAQ:FPRX)
Analysts' Ratings History for Five Prime Therapeutics (NASDAQ:FPRX)
Show:
DateFirmActionRatingPrice TargetImpact on Share PriceDetails
10/16/2017BMO Capital MarketsUpgradeMarket Perform -> OutperformN/AView Rating Details
9/14/2017Royal Bank Of CanadaInitiated CoverageOutperform -> Outperform$41.00HighView Rating Details
9/12/2017Jefferies Group LLCReiterated RatingBuy$52.00HighView Rating Details
3/24/2017Cowen and CompanyInitiated CoverageOutperformHighView Rating Details
3/1/2017InstinetInitiated CoverageBuy -> Buy$94.00N/AView Rating Details
3/1/2017NomuraInitiated CoverageBuyN/AView Rating Details
11/7/2016Credit Suisse GroupReiterated RatingBuy$54.00N/AView Rating Details
10/25/2016Citigroup Inc.Initiated CoverageBuy$65.00N/AView Rating Details
8/8/2016Leerink SwannReiterated RatingOutperform$45.00 -> $58.00N/AView Rating Details
5/19/2016Oppenheimer Holdings, Inc.Reiterated RatingOutperform$48.00N/AView Rating Details
12/4/2015Wells Fargo & CompanyReiterated RatingOutperformN/AView Rating Details
(Data available from 10/18/2015 forward)

Earnings

Earnings History for Five Prime Therapeutics (NASDAQ:FPRX)
Earnings by Quarter for Five Prime Therapeutics (NASDAQ:FPRX)
Earnings History by Quarter for Five Prime Therapeutics (NASDAQ FPRX)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
8/8/2017Q2 2017($1.15)($1.58)$8.32 million$7.80 millionViewListenView Earnings Details
5/4/2017Q1 2017($0.96)($1.21)$6.05 million$10.13 millionViewListenView Earnings Details
2/23/2017Q4 2016($0.57)($0.73)$7.09 million$8.30 millionViewN/AView Earnings Details
11/3/2016Q3($0.51)($0.72)$7.50 million$6.70 millionViewN/AView Earnings Details
8/4/2016Q2($0.56)($0.49)$6.38 million$9.23 millionViewN/AView Earnings Details
5/5/2016Q1($0.71)($0.49)$5.26 million$6.50 millionViewN/AView Earnings Details
3/10/2016Q4$9.67$10.63$354.16 million$363.34 millionViewListenView Earnings Details
11/4/2015Q315($0.99)($0.93)$4.90 million$5.90 millionViewN/AView Earnings Details
8/6/2015Q215($0.44)($0.45)$6.92 million$6.30 millionViewN/AView Earnings Details
5/13/2015Q1($0.46)($0.44)$4.77 million$4.30 millionViewListenView Earnings Details
3/17/2015Q414($0.40)($0.55)$5.39 million$4.65 millionViewN/AView Earnings Details
11/10/2014Q3 2014($0.40)($0.33)$5.22 million$6.06 millionViewN/AView Earnings Details
8/5/2014Q2 14($0.27)($0.46)$5.39 million$4.98 millionViewN/AView Earnings Details
3/25/2014Q4($0.40)($0.43)$1.52 million$3.79 millionViewListenView Earnings Details
11/12/2013($0.57)($2.74)ViewN/AView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for Five Prime Therapeutics (NASDAQ:FPRX)
2017 EPS Consensus Estimate: ($4.86)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20171($0.97)($0.97)($0.97)
Q2 20171($1.03)($1.03)($1.03)
Q3 20172($1.50)($1.34)($1.42)
Q4 20172($1.54)($1.34)($1.44)
(Data provided by Zacks Investment Research)

Dividends

Dividend History for Five Prime Therapeutics (NASDAQ:FPRX)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading and Institutional Ownership History for Five Prime Therapeutics (NASDAQ:FPRX)
Insider Ownership Percentage: 6.50%
Institutional Ownership Percentage: 84.05%
Insider Trades by Quarter for Five Prime Therapeutics (NASDAQ:FPRX)
Institutional Ownership by Quarter for Five Prime Therapeutics (NASDAQ:FPRX)
Insider Trades by Quarter for Five Prime Therapeutics (NASDAQ:FPRX)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
10/2/2017William R RingoDirectorSell1,800$40.26$72,468.00View SEC Filing  
9/28/2017William R RingoDirectorSell2,000$38.00$76,000.00View SEC Filing  
3/1/2017William R RingoDirectorSell500$46.73$23,365.00View SEC Filing  
2/1/2017William R RingoDirectorSell500$46.17$23,085.00View SEC Filing  
1/18/2017Francis Willard SarenaInsiderSell3,636$47.39$172,310.04View SEC Filing  
1/3/2017William R RingoDirectorSell500$51.07$25,535.00View SEC Filing  
12/23/2016Lewis T WilliamsCEOSell30,000$50.50$1,515,000.00View SEC Filing  
12/1/2016William R RingoDirectorSell500$57.72$28,860.00View SEC Filing  
11/28/2016Francis Willard SarenaInsiderSell1,710$60.14$102,839.40View SEC Filing  
11/25/2016Francis Willard SarenaInsiderSell34,654$60.38$2,092,408.52View SEC Filing  
11/9/2016Peder JensenDirectorSell8,130$55.30$449,589.00View SEC Filing  
11/1/2016William R RingoDirectorSell500$48.67$24,335.00View SEC Filing  
10/3/2016William R RingoDirectorSell500$52.00$26,000.00View SEC Filing  
9/1/2016William R RingoDirectorSell500$44.20$22,100.00View SEC Filing  
8/1/2016William R RingoDirectorSell500$50.77$25,385.00View SEC Filing  
7/27/2016Peder JensenDirectorSell12,195$49.50$603,652.50View SEC Filing  
4/22/2016Franklin M BergerDirectorBuy5,000$49.47$247,350.00View SEC Filing  
4/22/2016Marc BelskyCFOSell34,102$50.00$1,705,100.00View SEC Filing  
4/21/2016Lewis T WilliamsCEOSell48,671$48.05$2,338,641.55View SEC Filing  
4/19/2016Franklin M BergerDirectorBuy6,090$47.06$286,595.40View SEC Filing  
4/15/2016Lewis T WilliamsCEOSell1,405$48.00$67,440.00View SEC Filing  
4/14/2016Lewis T WilliamsCEOSell2,725$48.00$130,800.00View SEC Filing  
4/6/2016Lewis T WilliamsCEOSell52,801$43.09$2,275,195.09View SEC Filing  
4/6/2016Marc BelskyCFOSell20,814$45.04$937,462.56View SEC Filing  
3/30/2016Francis Willard SarenaEVPSell10,000$40.01$400,100.00View SEC Filing  
3/30/2016Lewis T WilliamsCEOSell23,259$40.02$930,825.18View SEC Filing  
3/30/2016Marc BelskyCFOSell13,876$40.01$555,178.76View SEC Filing  
3/2/2016Lewis T WilliamsCEOSell23,259$36.01$837,556.59View SEC Filing  
2/4/2016Lewis T. WilliamsCEOSell71,229$33.35$2,375,487.15View SEC Filing  
1/27/2016Francis Willard SarenaEVPSell30,000$35.22$1,056,600.00View SEC Filing  
10/15/2015Adage Capital Partners Gp LlcMajor ShareholderSell125,000$27.75$3,468,750.00View SEC Filing  
10/15/2015Lewis T. WilliamsCEOSell72,352$27.24$1,970,868.48View SEC Filing  
9/21/2015Lewis T WilliamsCEOSell2,648$22.06$58,414.88View SEC Filing  
6/22/2015Lewis T WilliamsCEOSell75,000$24.67$1,850,250.00View SEC Filing  
1/28/2015Franklin M BergerDirectorBuy25,000$27.03$675,750.00View SEC Filing  
1/15/2015Franklin M BergerDirectorBuy10,049$26.17$262,982.33View SEC Filing  
11/28/2014Franklin M BergerDirectorBuy1,951$21.04$41,049.04View SEC Filing  
11/4/2014Lewis T WilliamsCEOSell32,603$13.08$426,447.24View SEC Filing  
10/30/2014Lewis T WilliamsCEOSell17,397$13.13$228,422.61View SEC Filing  
9/23/2013Brian G AtwoodDirectorBuy76,923$13.00$999,999.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Headline Trends for Five Prime Therapeutics (NASDAQ:FPRX)
Latest Headlines for Five Prime Therapeutics (NASDAQ:FPRX)
Source:
DateHeadline
finance.yahoo.com logoETFs with exposure to Five Prime Therapeutics, Inc. : October 17, 2017
finance.yahoo.com - October 17 at 7:29 PM
benzinga.com logo35 Biggest Movers From Yesterday - Benzinga
www.benzinga.com - October 17 at 5:15 AM
americanbankingnews.com logoFive Prime Therapeutics, Inc. (FPRX) Upgraded to Buy by Zacks Investment Research
www.americanbankingnews.com - October 16 at 11:20 PM
nasdaq.com logoFive Prime Therapeutics, Inc. (FPRX) Jumps: Stock Rises 6.2% - Nasdaq
www.nasdaq.com - October 13 at 4:24 PM
finance.yahoo.com logoFive Prime Therapeutics, Inc. (FPRX) Jumps: Stock Rises 6.2%
finance.yahoo.com - October 13 at 4:24 PM
americanbankingnews.com logoContrasting Orexigen Therapeutics (OREX) and Five Prime Therapeutics (FPRX)
www.americanbankingnews.com - October 13 at 2:26 PM
globenewswire.com logoFive Prime Announces Cabiralizumab Phase 1a/1b Data Abstract Selected for Late ...
globenewswire.com - October 12 at 7:39 PM
streetinsider.com logoFive Prime Therapeutics (FPRX) Says Cabiralizumab Phase 1a/1b Data Abstract Selected for Late Breaking Oral ... - StreetInsider.com
www.streetinsider.com - October 11 at 4:37 PM
finance.yahoo.com logoFive Prime Announces Cabiralizumab Phase 1a/1b Data Abstract Selected for Late Breaking Oral Presentation at the Society for Immunotherapy of Cancer (SITC) 32nd Annual Meeting
finance.yahoo.com - October 11 at 4:37 PM
marketwatch.com logoCharting the S&P 500’s break to ‘clear skies’ technical territory
www.marketwatch.com - October 10 at 4:31 PM
finance.yahoo.com logoETFs with exposure to Five Prime Therapeutics, Inc. : October 6, 2017
finance.yahoo.com - October 6 at 7:12 PM
finance.yahoo.com logoFive Prime Therapeutics, Inc. :FPRX-US: Earnings Analysis: Q2, 2017 By the Numbers : October 5, 2017
finance.yahoo.com - October 5 at 6:00 PM
americanbankingnews.com logoFive Prime Therapeutics, Inc. (FPRX) Director Sells $72,468.00 in Stock
www.americanbankingnews.com - October 3 at 11:34 PM
americanbankingnews.com logoWilliam R. Ringo Sells 2,000 Shares of Five Prime Therapeutics, Inc. (FPRX) Stock
www.americanbankingnews.com - October 2 at 4:34 PM
americanbankingnews.com logoFive Prime Therapeutics, Inc. (FPRX) Expected to Post Quarterly Sales of $9.00 Million
www.americanbankingnews.com - October 2 at 11:04 AM
americanbankingnews.com logoFive Prime Therapeutics, Inc. (FPRX) Receives Consensus Recommendation of "Hold" from Analysts
www.americanbankingnews.com - September 30 at 6:36 PM
seekingalpha.com logoFive Prime Therapeutics (FPRX) Presents At LEERINK Partners Roundtable Series on Rare Disease and Immuno-Oncology - Slideshow
seekingalpha.com - September 29 at 2:36 PM
americanbankingnews.com logoFive Prime Therapeutics, Inc. (FPRX) Stock Rating Reaffirmed by BMO Capital Markets
www.americanbankingnews.com - September 22 at 4:36 PM
finance.yahoo.com logoFive Prime Therapeutics to Present at the LEERINK Partners Roundtable Series: Rare Disease & Immuno-Oncology
finance.yahoo.com - September 21 at 6:54 PM
americanbankingnews.com logoFive Prime Therapeutics (FPRX) & Its Peers Critical Comparison
www.americanbankingnews.com - September 21 at 6:26 AM
americanbankingnews.com logoFive Prime Therapeutics (FPRX) and Its Peers Critical Review
www.americanbankingnews.com - September 19 at 2:30 PM
americanbankingnews.com logoContrasting Five Prime Therapeutics (FPRX) & Dermira (DERM)
www.americanbankingnews.com - September 17 at 10:16 AM
streetinsider.com logoFive Prime Therapeutics (FPRX) Announces Licensing Agreement ... - StreetInsider.com
www.streetinsider.com - September 15 at 12:27 AM
americanbankingnews.com logoFive Prime Therapeutics, Inc. (FPRX) Receives New Coverage from Analysts at Royal Bank Of Canada
www.americanbankingnews.com - September 14 at 10:36 PM
globenewswire.com logoAblexis Announces Licensing of the AlivaMab Mouse to Five Prime Therapeutics
globenewswire.com - September 14 at 7:26 PM
streetinsider.com logoFive Prime Therapeutics (FPRX) Reports Preclinical Research Data on Novel B7-H4 Therapeutic Antibody at ESMO 2017
www.streetinsider.com - September 12 at 12:25 AM
benzinga.com logoArray BioPharma And Others Shine At ESMO 2017 Congress ... - Benzinga
www.benzinga.com - September 11 at 7:22 PM
streetinsider.com logoFive Prime Therapeutics (FPRX) Reports Updated Data in Mesothelioma Patients from Ongoing Phase 1b Trial of FP ... - StreetInsider.com
www.streetinsider.com - September 11 at 7:22 PM
streetinsider.com logoFive Prime Therapeutics (FPRX) Reports Preclinical Research Data on Novel B7-H4 Therapeutic Antibody at ESMO 2017 - StreetInsider.com
www.streetinsider.com - September 11 at 7:22 PM
americanbankingnews.com logo Analysts Expect Five Prime Therapeutics, Inc. (FPRX) to Announce -$1.32 EPS
www.americanbankingnews.com - September 11 at 2:16 PM
nasdaq.com logoFive Prime Announces Updated Data in Mesothelioma Patients from Ongoing Phase 1b Trial of FP-1039 at ESMO ... - Nasdaq
www.nasdaq.com - September 10 at 5:57 PM
globenewswire.com logoFive Prime Presents Preclinical Research Data on Novel B7-H4 Therapeutic Antibody at ESMO 2017 Congress - GlobeNewswire (press release)
globenewswire.com - September 10 at 5:57 PM
finance.yahoo.com logoFive Prime Announces Updated Data in Mesothelioma Patients from Ongoing Phase 1b Trial of FP-1039 at ESMO 2017 Congress
finance.yahoo.com - September 10 at 5:57 PM
finance.yahoo.com logoFive Prime Presents Preclinical Research Data on Novel B7-H4 Therapeutic Antibody at ESMO 2017 Congress
finance.yahoo.com - September 10 at 5:57 PM
americanbankingnews.com logoFive Prime Therapeutics, Inc. (FPRX) Receives Average Rating of "Hold" from Brokerages
www.americanbankingnews.com - September 5 at 9:26 PM
streetinsider.com logoFive Prime Therapeutics (FPRX) Announces Abstract with Updated Data in Mesothelioma Patients from Ongoing Phase 1b Trial of FP-1039 at ESMO
www.streetinsider.com - September 2 at 12:11 AM
streetinsider.com logoFive Prime Therapeutics (FPRX) Announces Abstract with Updated Data in Mesothelioma Patients from Ongoing ... - StreetInsider.com
www.streetinsider.com - September 1 at 7:10 PM
finance.yahoo.com logoFive Prime Announces Abstract with Updated Data in Mesothelioma Patients from Ongoing Phase 1b Trial of FP-1039 at ESMO 2017 Congress
finance.yahoo.com - September 1 at 7:10 PM
nasdaq.com logoFive Prime to Feature Two Oral Data Presentations at ESMO 2017 Congress - Nasdaq
www.nasdaq.com - August 30 at 12:22 AM
finance.yahoo.com logoFive Prime Therapeutics, Inc. – Value Analysis (NASDAQ:FPRX) : August 30, 2017
finance.yahoo.com - August 30 at 12:22 AM
finance.yahoo.com logoFive Prime to Feature Two Oral Data Presentations at ESMO 2017 Congress
finance.yahoo.com - August 29 at 7:18 PM
streetinsider.com logoFive Prime Therapeutics (FPRX) to End GITR License Agreement with Inhibrx - StreetInsider.com
www.streetinsider.com - August 29 at 4:35 AM
streetinsider.com logoFive Prime Therapeutics (FPRX) to End GITR License Agreement with Inhibrx
www.streetinsider.com - August 28 at 6:32 PM
finance.yahoo.com logoFive Prime Therapeutics, Inc. breached its 50 day moving average in a Bullish Manner : FPRX-US : August 23, 2017
finance.yahoo.com - August 24 at 2:37 AM
americanbankingnews.com logo Analysts Anticipate Five Prime Therapeutics, Inc. (FPRX) Will Announce Earnings of -$1.32 Per Share
www.americanbankingnews.com - August 24 at 12:18 AM
nasdaq.com logoNoteworthy Friday Option Activity: FPRX, LULU, GOOGL
www.nasdaq.com - August 18 at 6:42 PM
globenewswire.com logoFive Prime Therapeutics Announces Addition of Bryan Irving, PhD, as Senior Vice President, Research - GlobeNewswire (press release)
globenewswire.com - August 17 at 8:03 PM
finance.yahoo.com logoFive Prime Therapeutics Announces Addition of Bryan Irving, PhD, as Senior Vice President, Research
finance.yahoo.com - August 17 at 8:03 PM
finance.yahoo.com logoSee what the IHS Markit Score report has to say about Five Prime Therapeutics Inc.
finance.yahoo.com - August 14 at 7:09 PM
americanbankingnews.com logoFive Prime Therapeutics, Inc. (FPRX) Given Consensus Recommendation of "Hold" by Brokerages
www.americanbankingnews.com - August 11 at 9:06 PM

Social

Chart

Five Prime Therapeutics (FPRX) Chart for Wednesday, October, 18, 2017

This page was last updated on 10/18/2017 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.